N/A N=100 PROLONG Prospective, Multi-center, Open-label, Post-market Study
Chronic Pain
Primary: Mean Change in Pain Assessed by Numerical Rating Scale (NRS) From Baseline to 3 Months — 2.3; 3.3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=11 Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Ligneous Conjunctivitis
Primary: Percentage of Success to Prevent Pseudomembranes Relapse — 75; 81.8; 100; 100 percentage of eyes
N/A N=233 An Internet Based Adaptation of a Divorce Intervention Beginnings Program for Divorced Parents
Divorce
Primary: Children's Perception of Interparental Conflict Scale (Grych et al., 1992) -- Children Report Version — 1.30; 1.47 Score on the scale — p=0.02
N/A N=1,164 A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Adverse Drug Reactions (ADRs) — 32 Participants
Phase 1 N=47 A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Maximum Observed Concentration (Cmax) of BGF MDI — 552.2; 483.2; 489.4; 11.74 pg/mL
N/A N=72 Evaluation of Visual Acuity With a Reusable Toric Multifocal Contact Lens
Visual Acuity
Primary: Binocular High Luminance High Contrast logMAR Visual Acuity — -0.13; -0.02; 0.09 LogMAR
Phase 2 N=31 Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Hodgkin's Lymphoma · Lymphoid Leukemia · Lymphoma
Primary: The Number of Patients With Relapse-free/Donor Lymphocyte Infusion(DLI)-Free Survival Rates Between Patients Randomized to MMF-30 (Control Cohort) and MMF-15…
Phase 2 N=27 Single Dose Intranasal Oxytocin and Cognitive Effects in Autism
Autism Spectrum Disorders
Primary: Reading the Mind in the Eyes Task (RMET) — 18.07; 18.08; 17.86; 18.09 total raw score
N/A N=121 Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial Folds
Correction of Moderate to Severe Nasolabial Folds (NLFs)
Primary: Change From Baseline to Week 24 on the Wrinkle Severity Rating Scale (WSRS) — 3.4; 3.4; 2.4; 2.4 score on a scale
Phase 1 N=57 Development of a mHealth Intervention for Ambivalent Smokers
Tobacco Use Disorder · Smoking Cessation · Motivation
Primary: Program Engagement — 7.3; 19.9 User sessions — p=<0.01
N/A N=217 Rectal Microbicide Acceptability, Tolerability and Adherence
HIV Prevention
Primary: Acceptability of Future Product Use — 143; 132; 143; 56 Participants
Phase 1 N=1 Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Diseases
Primary: Number of Subjects Who Experience Serious Adverse Events, Adverse Events, and/or Early Treatment Discontinuations. — 1 Participants
N/A N=177 Shifting Perspectives: Enhancing Outcomes in Anorexia Nervosa With CRT
Anorexia Nervosa
Primary: Change in Cognitive Flexibility - Condition 4 Trail Making Test of DKEFS — 11.89; 10.94; 11.47; 11.14 score on a scale — p=.507
N/A N=15 Two Way Crossover Closed Loop Study R-AP vs MPC
Type 1 Diabetes
Primary: Area Under the Curve (AUC) of Postprandial Glucose — 277.5; 253.9 mg/dL*hr
Phase 3 N=355 A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
Molluscum Contagiosum
Primary: Complete Clearance of All Treatable MC at Week 12 — 71; 24 Participants